Vaccines engineered to elicit responses against the BRAF <sup><i>V</i>600<i>E</i></sup> mutation, RET/PTC fusions, and additional neoantigens have shown promising immunogenic profiles in preliminary trial cohorts, while adoptive transfer methodologies, including tumor-infiltrating lymphocyte (TIL) mobilization and engineered CAR-T lymphocytes, are progressing through preclinical and early-phase clinical benchmarks. The gene discussed is RET; the disease is neoplasm.